An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes

Novo Nordisk A/S2,275 enrolled

Overview

The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes (T2DM) patients across five selected countries in Europe. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than what has been prescribed to them by their doctor. Participants' participation will be one day/one visit at study doctor. The study will last for about 3 months in total.

Study Type

OBSERVATIONAL

Enrollment

2,275

Conditions

Diabetes Mellitus, Type 2

Interventions

No treatment givenOTHER

No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * Male or female, age greater than or equal to 18 years at the time of signing informed consent * Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of signing the informed consent Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study * Diagnosed with Type 1 diabetes * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Patients with known congenital heart disease/malformation

Locations (41)

Outcomes

Primary Outcomes

Diagnosed with cerebrovascular disease: Ischaemic stroke, haemorrhagic stroke, stroke (unspecified) and/or transient ischaemic attack

Percentage of participants (Y/N).

Time frame: Day 1

Diagnosed with CVD: Myocardial infarction, stable coronary artery disease (SCAD) also referred as angina (pectoris), other ischaemic heart disease and/or past revascularisation procedures

Percentage of participants (Y/N).

Time frame: Day 1

Diagnosed with symptomatic heart failure: New York Heart Association Functional Classification (NYHA) (group IIIV) and/or left ventricular ejection fraction (LVEF) greater than or equal to 50 percent, LVEF 40-49 percent and LVEF less than 40 percent)

Percentage of participants (Y/N).

Time frame: Day 1

Diagnosed with asymptomatic heart failure

Percentage of participants (Y/N).

Time frame: Day 1

Hospitalisation for heart failure

Percentage of participants (Y/N).

Time frame: Day 1

Diagnosed with cardiac arrhythmia: Atrial fibrillation or flutter, ventricular tachycardia and/or ventricular fibrillation

Percentage of participants (Y/N).

Time frame: Day 1

Diagnosed with aortic diseases: Aortic dissection, aortic aneurysms and/or thromboembolic aortic disease

Percentage of participants (Y/N).

Time frame: Day 1

Diagnosed with peripheral artery disease: Asymptomatic peripheral arterial disease (PAD) defined as Low Ankle-Brachial Index (less than 0.90) or pulse abolition, claudication, limb ischemia and/or non-traumatic amputation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.